Identifying pathogens in febrile patients using gene expression
Official title: A Multisite Evaluation of Functional Genomic Signatures for the Improved Diagnosis of Acute Undifferentiated Febrile Infections
Run by University of Sheffield · NCT04878549 · Data updated 2026-11-12
This study is trying to find out if looking at gene responses in feverish patients can help doctors quickly tell if they have enteric fever or another infection, especially in places with limited resources.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 2 Years to 65 Years |
| Sex | All |
| Enrollment | 2000 (estimated) |
| Sponsor | University of Sheffield Academic / other |
| Locations | 1 site (Vellore) |
| Status | Recruiting |
| Started | May 2, 2022 |
| Main results expected | June 2025 |
| Study ends | June 2025 |
| Registry record updated | March 3, 2025 |
| Trial ID | NCT04878549 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are febrile adults aged 15 to 65 who present with fever without localizing features or have recently confirmed enteric fever.
✕Probably not a fit
Patients who are unable to provide informed consent or do not have a next of kin willing to assist will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to improve diagnostics for acute undifferentiated febrile infections (AUFI) by evaluating host gene expression responses in endemic populations. By collecting clinical and laboratory data from febrile adults in low-resource settings, the study seeks to identify gene expression signatures that can differentiate enteric fever from other causes of AUFI. The ultimate goal is to develop a point-of-care test based on these signatures to enhance patient management and disease prevention in low- and middle-income countries.
Why it matters
Potential benefit: If successful, this study could lead to more accurate and timely diagnoses of enteric fever, improving patient outcomes and guiding effective treatment.
How similar studies have gone: Other studies have shown promise in using gene expression profiling for pathogen identification, indicating that this approach may be effective.
Who can join: the full rules
Show full inclusion / exclusion criteria
FEBRILE ADULTS- INCLUSION CRITERIA
* Age greater than or equal to 15 years and less than or equal to 65 years
* Participant is willing and they and/or an appropriate guardian/relative/representative is able to give informed consent for participation in the study and a follow-up (telephone) discussion at 14 days
* And either:
1. Febrile illness without localising features (see 'exclusion criteria' and 'screening' sections) where fever is defined as:
* documented tympanic/rectal temperature of ≥ 38°C or an axillary/oral temperature of ≥ 37.8°C, or a reported fever within the last 24 hours and
* Reported duration of fever 3-14 days or
2. Recently confirmed blood culture indicating enteric fever (confirmed within the previous 5 days)
* They may have had recent exposure to antimicrobials.
FEBRILE ADULTS- EXCLUSION CRITERIA
* The participant may not enter the study if ANY of the following apply:
* Unable to provide informed consent and no next of kin is willing and able to provide informed consent.
* For patients with febrile illness (included in (1) above): Any history or clinical suspicion of:
* Rheumatological or connective tissue disorder (e.g. Rheumatoid arthritis)
* Autoimmune condition (e.g. Autoimmune Hepatitis)
* Malignancy
* Active treatment with immunomodulating medications, or for tuberculosis (pulmonary or extrapulmonary) or any other chronic infection.
* Pregnancy (breast feeding mothers will NOT be excluded)
* No hospitalisation for more than 48 hours in the last 4 weeks
* Vaccination within 4 weeks prior to current admission
* Localising signs or symptoms of infection sufficient to diagnose the likely cause of acute febrile illness and thus prevent it from being 'undifferentiated.'
CONTROLS- INCLUSION CRITERIA
* Participant is willing and they are (and in 15-18 year olds, a guardian is) able to give informed consent for participation in the study
* Age greater than or equal to 15 years and less than or equal to 65 years
* They live outside of the normal/local catchment area for each hospital site
* Afebrile (as defined by no reported fever and temperature ≤ 38°C or an axillary/oral temperature of ≤ 37.8°C).
CONTROLS- EXCLUSION CRITERIA
* The participant may not enter the study if ANY of the following apply:
* Unable to provide informed consent and no next of kin (or parent/guardian in the case of a minor) is willing and able to provide informed consent.
* Current treatment for or prior history, or clinical suspicion of:
* Rheumatological or connective tissue disorder
* Autoimmune condition
* Malignancy
* Active treatment for tuberculosis (pulmonary or extrapulmonary) or clinical suspicion of active tuberculosis. Previous completed treatment is not a reason for exclusion.
* Active treatment with immunomodulating medications or any other chronic infection.
* Pregnant (breast feeding mothers will NOT be excluded)
* Hospitalisation within 4 weeks of recruitment
* Vaccination within 4 weeks prior to recruitment
* Antimicrobial use within 4 weeks of recruitment
* Participant reports feeling more unwell than usual on the day of enrolment.
EXPLORATORY AIMS- PAEDIATRIC CRITERIA; INCLUSION CRITERIA
* Age greater than or equal to 2 years and less than 15 years
* As above for adult participants.
EXPLORATORY AIMS- PAEDIATRIC CRITERIA; EXCLUSION CRITERIA
* Parent/guardian is unwilling, and/or patient aged 8 to 14 years is unwilling to assent to provide informed consent.
* As above for adult participants.
Where it's running
-
Christian Medical Centre
Vellore, India Recruiting
Study contacts
- Study coordinator: Farah Shahi
- Email: f.shahi@sheffield.ac.uk
- Phone: 01142159522
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
See if Buzzy and virtual reality help kids get IV lines faster
This study tests whether a vein-imaging device plus virtual reality or the same device plus a pain-reducing tool can make peripheral IV placement easier for children aged 7–12 with fever.
-
Triage performance and physiological predictors of serious illness in febrile children in the pediatric emergency department
This study tests whether the initial color-coded triage category and vital signs at triage can predict serious outcomes in febrile children who come to pediatric emergency departments in Turkey.
-
Turning anonymous symptom descriptions into structured biological signals with OpenGenome
This project tries to turn adults' anonymous free-text symptom descriptions submitted to OpenGenome into structured, literature-grounded biological signals using PubMed and ClinicalTrials.gov sources and a constrained reasoning model.
-
IV azithromycin versus meropenem for extensively drug-resistant (XDR) enteric fever
This tests whether intravenous azithromycin or meropenem works better for people aged 1–70 with blood-culture-confirmed XDR enteric fever.
-
How long to take sulfamethoxazole after a kidney transplant
This study will test whether different lengths of sulfamethoxazole (TMP‑SMX) taken after a kidney transplant better prevent Pneumocystis jirovecii pneumonia in adult transplant recipients.
-
Safety of giving an RSV preventive antibody with routine childhood vaccines
This trial will test whether giving an RSV preventive antibody at the same visit as routine childhood vaccines is as safe for infants 6 to <30 weeks old as giving the antibody at a separate visit.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.